Kornimate/medical-research-clean huggingface dataset:
data collection atrial fibrillation exploratory study

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: to characterize the impact of atrial fibrillation (afib) and atrial flutter (afl) on signals measured using a wearable cardiac monitor prototype device. to evaluate the relationship of afib/afl symptom severity with various physiologic signals measured from the wearable cardiac monitor prototype device.

the is a non-randomized feasibility study that will enroll up to 50 participants with an ongoing episode of afib/afl and are referred for a cardiac ablation or electrical cardioversion procedure. a maximum of 20 persistent afib, 20 paroxysmal afib, and 20 afl participants will be enrolled, not to exceed 50 total. there will be up to three data collection visits. visit 1 will occur on the same day as enrollment and prior to the cardiac ablation or electrical cardioversion procedure. this allows collection of physiologic signals while the patient is in afib or afi. visit 2 will occur after the cardiac ablation or electrical cardioversion procedure; no earlier than the day after the cardiac ablation or electrical cardioversion procedure and no more than 4 months after the day of the procedure. visit 3 is optional, and may be scheduled upon sponsor's request, which will take place at least 5 months after the previous (second) data collection visit.

Eligibility criteria:
inclusion criteria: * able to understand and willing to provide written informed consent to participate in the trial * age 18 years old or greater * willing and able to participate in study visits and the required testing * diagnosed with paroxysmal afib or persistent afib or afl and scheduled for a cardiac ablation or electrical cardioversion procedure * confirmed afib/afl at the time of enrollment exclusion criteria: * currently enrolled in another clinical trial that may interfere with the placement of study system or include the usage of unapproved drugs * participant is pregnant or planning to become pregnant during the study * diagnosed with permanent afib * active implantable medical device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc. * known allergy to materials used in the study (adhesive tape, ecg electrodes) * have a prosthetic cardiac valve or previously underwent cardiac valve surgery.

Keywords: atrial fibrillation atrial flutter arrhythmia
effects of neuropilates on rehabilitation programs for chronic stroke

Conditions: Stroke; Occupational Therapy; Physiotherapy

Summary: introduction: cerebrovascular damage (stroke) can generate motor or cognitive sequelae, making rehabilitation (such as the pilates method) necessary to improve autonomy and quality of life. however, there are no studies on the efficacy of the method in the recovery of the upper limb and the improvement of autonomy after stroke. methods: randomized double-blind clinical trial with patients with stroke in semi-acute period, randomized into experimental group (eg) (conventional rehabilitation and pilates) or control group (cg) (conventional rehabilitation). after randomization and initial evaluation, the intervention will begin (2 sessions per week, 3 months). after completion, there will be post-intervention assessment, and another one at 1 month. intervention: the cg will receive 30 minutes of physical therapy and 30 minutes of occupational therapy. the sg will receive 20 minutes of physiotherapy, 20 minutes of occupational therapy and 20 minutes of pilates. assessment instruments: mean functional independence; functional range test; timed 'up and go'; nine hole peg test; box and block test; arm, shoulder and hand disabilities questionnaire; client satisfaction questionnaire.


Eligibility criteria:
inclusion criteria: 1. present a diagnosis of ischemic or hemorrhagic stroke with a minimum evolution of 3 months; 2. be over 18 years of age; 3. regularly attend rehabilitation treatment at the physiocare madrid center; 4. present moderate functional problems (score greater than 65 on the barthel index); 5. not present moderate cognitive impairment (mini mental state examination less than 18 points); 6. not present nasogastric tubes; 7. accept to participate voluntarily in the study and sign the informed consent form; 8. be able to participate in the study and sign the informed consent form. exclusion criteria: 1. time of evolution of less than 3 months; 2. other conditions of the central nervous system (tumors, anoxia, cranioencephalic trauma, etc.); 3. cardiorespiratory or neurodegenerative disorders, severe brain damage or a score of 6 or higher on the reisberg deterioration scale (gds); 4. a severely impaired level of consciousness or a score of 8 or lower on the glasgow coma scale (gcs); 5. receiving other complementary rehabilitative therapy; 6. a severe deterioration in the level of consciousness or a score of 8 or lower on the glasgow coma scale (gcs); 7. a severe deterioration in the level of consciousness or a score of 8 or lower on the glasgow coma scale (gcs); 8. a severe deterioration in the level of consciousness or a score of 8 or lower on the glasgow coma scale (gcs).
reliability, validity of the turkish version of fonseca anamnestic index

Conditions: Temporomandibular Joint Disorders

Summary: the aim in this study is to determine the turkish version validity and reliability of the fonseca anamnestic index.

approximately 60% of individuals with temporomandibular disorders (tmd) reported increased pain intensity from midlevel to severe. this was seen at the end of the intervention or work related activities in the quarter of individuals. therefore, the correct diagnosis of tmd is very important to reduce the economic cost. fonseca anamnestic index (fai) is an easy and understandable questionnaire. this questionnaire consists of 10 questions that provide a versatile evaluation of the temporomandibular joint (tmj) in the head and neck, whether there is pain during chewing, the presence of parafunctional habits, range of motion, joint sounds, malocclusion, and emotional stresses. the participants give one of the answers to the questions "yes = 10 points, sometimes = 5 points, no = 0 points". as a result of the total of the points, the participants are evaluated as "tmd-none = 0-15 points, mild-tmd = 20-40 points, moderate tmd = 45-60 points, severe-tmd = 100 points". the aim of this study was to evaluate the validity and reliability of the turkish version of fai. the study of validity and reliability is planned with 50 individuals with tmd. the sociodemographic characteristics of the individuals will be questioned by the investigators and then the patients will be evaluated with fai, craniofacial pain and disability inventory (cf-pdi), neck disability index (ndi), tampa scale for kinesiophobia (tsk), pain catastrophizing scale (pcs), headache impact test-6 (hit-6), jaw functional limitation scale (jfls) (turkish version) and visual analogue scale (vas). the test-retest will be re-administered by face-to-face interview technique after 1 week. the results will be analyzed using the spss version 22.0 computer package program.

Eligibility criteria:
inclusion criteria: * having a temporomandibular disorder * individuals who suited temporomandibular disorders/ research diagnostic criteria classification exclusion criteria: * pregnant, * canser, * trauma, * neurologic disorder, * infection, * trigeminal or postherpatic neuralgia

Keywords: validity reliability temporomandibular joint disorders
optimization dose study on pharmacokinetics and pharmacodynamics of colistin in critically ill patients

Conditions: Critical Illness

Summary: phase ii clinical trial, open-labelled, prospective and single-center study directed to obtain blood samples in experimental detailed conditions in order to compare and optimize the dose of colistin in critically ill patients suffering from infections on which the indication of colistin would be accepted according to normal local protocols for severe infections treatment.


Eligibility criteria:
inclusion criteria: * more than 60 kg of weigh * patients with directed treatment with colistin as the recommended antimicrobial treatment protocols in the hospital to treat some of the following serious infections caused by carbapenems resistant a. baumannii: (i) bacteremia; (ii) nosocomial pneumonia or (iii) infection of skin and soft tissue (cellulitis, abscesses or infected ulcers). * written informed consent form. exclusion criteria: * refractory shock or other illness with an expectative of life ˂ 48 hours after the recruitment; * patient declared not to resuscitation maneuvers; * suspicion or demonstration of endocarditis, osteomyelitis, or meningitis; * known hypersensitivity to polymyxins; * pregnancy.

Keywords: infections multidrug resistant gram negative bacteria (mdr-gnb) skin infections pneumonia bacteriemia nosocomial infections
transsternal versus transcervical thymectomy

Conditions: Myasthenia Gravis, Thymectomy

Summary: objective: to comparatively analyze long-term results and complications of transcervical (tct) and transsternal thymectomy (tst) in a randomized controlled trial with a mean follow-up of ten years. results: outcomes 10 years after surgery by mgfa post-intervention status showed that complete stable remission was achieved in 8 (21.6%) patients of the tct group, and in 20 patients (55.5%) of the tst group. conclusions: transcervical and transsternal thymectomy are safe and result in significant improvement of patients with myasthenia gravis. tst has superior results in terms of complete stable remission at 10 years.

background: thymectomy is an effective treatment for myasthenia gravis in the adult population. surgical removal of the thymus can be performed through several approaches. comparison of the most commonly used surgical techniques through randomized control trials with long-term follow-up is scarce. objective: to comparatively analyze long-term results and complications of transcervical (tct) and transsternal thymectomy (tst) in a randomized controlled trial with a mean follow-up of ten years. results: a total of 100 patients were randomized to transsternal thymectomy (50), and transcervical procedure (50). there were not significant differences in the demographic characteristics, mgfa clinical classification, and mgfa therapy status between groups before surgery. twenty patients were lost of follow up during the first year and were excluded. our final group included 40 patients in each group. three patients in tct group (7.5%) and 6 patients in the tst group (15%) developed surgical complications. at 1 year of follow-up, 7 patients (17.5%) of the tct group were asymptomatic in comparison with 15 patients (37.5%) of group tst, after 10 years of follow-up, 26 cases (72.9%) in group tct were asymptomatic in comparison with 29 cases (80.5%) of group tst. outcomes 10 years after surgery by mgfa post-intervention status showed that complete stable remission was achieved in 8 (21.6%) patients of the tct group, and in 20 patients (55.5%) of the tst group. conclusions: transcervical and transsternal thymectomy are safe and result in significant improvement of patients with myasthenia gravis. tst has superior results in terms of complete stable remission at 10 years.

Eligibility criteria:
inclusion criteria: inclusion criteria were a clinical diagnosis of mg confirmed by biochemical or physiologic studies and a ct excluding thymoma. - exclusion criteria: exclusion criteria were contraindications for major surgery.
longitudinal changes in serum kl-6 in ipf

Conditions: Idiopathic Pulmonary Fibrosis

Summary: idiopathic pulmonary fibrosis (ipf) is a chronic lung disease with a poor prognosis. more accurate tests to predict disease progression and response to treatment are required. krebs von den lungen-6 (kl-6) is a blood marker associated with ipf. results from previous studies have shown that levels of kl-6 are higher in patients with ipf compared to people without the disease. in addition, it is not clear what impact treatment has on kl-6 levels, and whether this could help us to monitor how effective treatment for ipf is. the investigators plan to perform a study in which kl-6 levels in the blood of patients with a new diagnosis of ipf are measured at baseline, 3, 6 and 12 months to look for and changes in the levels of kl-6 in the blood.

idiopathic pulmonary fibrosis (ipf) is a chronic lung disease with a poor prognosis. effective treatment which slows the progression of ipf has recently become available however, it is costly and at present is limited to patients who meet specific criteria based on their breathing tests. the breathing tests currently available to monitor progression of the disease are not always reliable and do not predict which patients will respond to treatment. more accurate tests to predict disease progression and response to treatment are required. krebs von den lungen-6 (kl-6) is a blood marker associated with ipf. results from previous studies have shown that levels of kl-6 are higher in patients with ipf compared to people without the disease. the majority of studies using kl-6 in ipf have taken place in japan and there is limited evidence of how useful it is in a european population. in addition, it is not clear what impact treatment has on kl-6 levels, and whether this could help us to monitor how effective treatment for ipf is. the investigators plan to perform a study in which kl-6 levels in the blood of patients with a new diagnosis of ipf are measured at baseline, 3, 6 and 12 months to look for and changes in the levels of kl-6 in the blood the objective of this study is to assess changes in serum kl-6 levels in patients with ipf over a 12-month period and assess if this correlates with changes in lung function and if kl-6 levels change in response to treatment with antifibrotic therapy.

Eligibility criteria:
inclusion criteria: * age 18 or older * multi-disciplinary team (mdt) diagnosis of idiopathic pulmonary fibrosis as per international consensus guidelines exclusion criteria * significant respiratory co-morbidity (i.e. where the major respiratory diagnosis is not ipf) * fev1/fvc ratio \< 70% on full lung function testing * current smoker (within 4 week of enrollment) * received treatment for acute lower respiratory tract infection with last 4 weeks * use of long-term (greater than 4 weeks) oral corticosteroids or immunosuppression within 4 weeks of enrolment * current participation in a double-blind placebo-controlled pharmaceutical trial

Keywords: kl-6 krebs von den lungen-6 biomarker
study to evaluate safety & efficacy of topical atx201 ointment in adolescents and adults with mild to moderate ad

Conditions: Atopic Dermatitis

Summary: this is a phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical atx201 ointment in adolescents and adults with mild to moderate atopic dermatitis

this is a phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical atx201 ointment in adolescents and adults with mild to moderate atopic dermatitis. approximately 210 subjects will be randomly assigned to receive atx201 ointment 4%, atx201 ointment 7%, or ointment vehicle for 6 weeks. treatments will be balanced into consecutive blocks in 1:1:1 ratio for the active groups and vehicle. sixteen additional subjects (adults and adolescents) will be enrolled in a 2-week open label substudy of twice-daily atx201 ointment 7% to evaluate the pk profile of atx201.

Eligibility criteria:
inclusion criteria (main ones): 1. diagnosis of ad using the hanifin and rajka criteria and minimum 1-year history with a current iga score of 2 or 3 and treatable bsa ≥5% but ≤36% (treatable bsa includes all lesions present at screening except scalp) 2. age ≥12 and \<60 years 3. male or nonpregnant and nonlactating female who is abstinent or agrees to use effective contraceptive methods throughout the course of the study. females must have a negative urine beta-human chorionic gonadotropin hormone (hcg) pregnancy test at day 1. 4. subject or lar able to understand and provide signed informed consent. assent is also required of adolescents. 5. normally active and otherwise in good health by medical history and physical examination exclusion criteria (main ones): 1. actively infected ad (ie, requiring antimicrobial therapy as determined by the investigator) 2. acute exacerbation or flare in the 4 weeks prior to the day 1 visit that necessitates treatment with a high potency corticosteroid (such as clobetasol propionate or betamethasone dipropionate), or antibiotics, or prednisolone 3. enrollment in an atx201 study in the previous 6 months 4. allergy or history of significant adverse reaction to atx201 or related compounds, or to any of the excipients used 5. underlying skin condition that may interfere with the placement of study treatment or impede clinical evaluations (including active herpes simplex) 6. current acute or chronic condition unless considered clinically irrelevant and stable by the investigator 7. the presence of a condition the investigator believes would interfere with the ability to provide informed consent or assent, or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk 8. unable or unwilling to comply with study procedures 9. exposure to any ip within 30 days prior to randomization there are also some specific criteria related to prior or concomitant therapy
risk factors and deep learning model for ci-aki

Conditions: AKI - Acute Kidney Injury

Summary: contrast-associated acute kidney injury (ci-aki) is a sudden and significant decline in renal function resulting from the use of a contrast agent.

contrast-associated acute kidney injury (ci-aki) is a sudden and significant decline in renal function resulting from the use of a contrast agent. despite the frequent use of iodinated contrast agents in medical investigations, predictive models for ci-aki are scarce. this study aimed to construct and validate interpretable deep learning models for the early risk prediction of acute kidney injury (aki) associated with iodinated contrast agents.

Eligibility criteria:
inclusion criteria: * patients who received iodinated contrast agents during hospitalization * age ≥ 18 years * hospitalization length ≥ 48 hours * at least two serum creatinine tests during hospitalization exclusion criteria: * patients with stage 4 or 5 chronic kidney disease prior to admission * patients undergoing hemodialysis, hemofiltration or peritoneal before admission * a history of nephrectomy or kidney transplantation during hospitalization * incomplete clinical information * serum creatinine always ≤ 40 μmol/l during hospitalization
the effect of phentermine and b12 on weight loss among obese patients

Conditions: Obesity; Hypertension

Summary: this is a pilot study designed to test the hypothesis that the combination of phentermine and b12 will result in significantly greater weight loss among obese patients compared to phentermine alone.

this pilot study is a double blind, randomized controlled trial designed to determine the significance of the combination therapy of phentermine and b12 injections among the obese population. the study population will be recruited from the ecu physicians internal medicine clinic. physicians will select patients meeting inclusion and exclusion criteria from their clinic to be approached for recruitment. approximately 30 patients will be recruited and blindly randomized to either the treatment group (phentermine and b12 in combination) or the control group (phentermine alone). patients will be randomized by means of block randomization in a 1:1 ratio. neither patients nor study team members will be aware of group assignments through the entire duration of the study. once randomized, both groups will begin taking 37.5 mg/day orally of phentermine as well as receive weekly intramuscular injections of either 1000 mg b12 or saline depending on their group assignment. the study will consist of approximately 15 visits over the course of 3 months.

Eligibility criteria:
individuals can participate in the study if they meet the following inclusion criteria: * are over the age of 18 * have a bmi between 30 and 40 * have a controlled blood pressure * do not have a b12 deficiency * are willing to take birth control (if female and not sterile or through menopause) * are english speaking individuals should not participate in if any of the following apply to them: * are not over the age of 18 * do not have a bmi between 30 and 40 * do not have a controlled blood pressure * have a b12 deficiency * females who are pregnant, trying to get pregnant, or not willing to use a method of birth control to ensure they do not become pregnant * individuals who do not speak english * individuals currently taking adderall, ritalin, or any other stimulant medication * individuals who have taken phentermine more than once in the past, or within 3 months of study initiation
effects of early sleep after action observation and motor imagery after metacarpal fracture surgery

Conditions: Hand Injuries; Action Observation; Motor Imagery

Summary: the study aimed to investigate the effects of early sleep after action observation and motor imagery (aomi) training sessions on manual dexterity in patients with hand immobilization after surgical fixation for metacarpals and phalanges fractures. fifty-one patients with hand immobilization for surgical fixation of iv or v metacarpals or first phalanges fractures will be randomized into aomi-sleep (n=17), aomi-control (n=17), and control (n=17) group. aomi-sleep and aomi-control groups will perform an aomi-training before sleeping or in the morning respectively, while control group will be asked to observe landscape video-clips. participants will be assessed for manual dexterity, hand range of motion, hand disability and quality of life at baseline before and after the training and at 1 month after the training end.

the study aimed to investigate the effects of early sleep after action observation and motor imagery (aomi) training sessions on manual dexterity in patients with hand immobilization after surgical fixation for metacarpals and phalanges fractures. fifty-one patients with right hand immobilization for surgical fixation of iv or v metacarpals or first phalanges fractures will be randomized into an aomi-sleep (n=17), aomi-control (n=17), and control (n=17) group. aomi-sleep and aomi-control groups will perform a 2-week aomi-training including transitive manual dexterity tasks between 8:00 and 10:00 p.m. or between 8:00 and 10:00 a.m. respectively, while control group participants will be asked to observe landscape video-clips between 8:00 and 10:00 p.m. participants will be assessed for manual dexterity (purdue pegboard test and kinematic indexes during nine hole peg test), hand range of motion (total active motion) hand disability (quick-dash) and quality of life (eq5d) at baseline (1 week after surgery), training end (3 weeks after surgery) and 1 month after the training end (7 weeks after surgery).

Eligibility criteria:
inclusion criteria: * surgical fixation for iv or v mtc or p1 fracture at the level of the right hand * age 18-40 years old * right-hand dominance exclusion criteria: * damage to additional hand structure requiring surgery (e.g. tendons, ligaments and nerves) * occurrence of left upper limb injuries * post-surgical complications (e.g. cprs) * immobilization \ 30 days * diagnosis of neurological/musculoskeletal conditions * sports or activities requiring advanced manual skills or sleep deprivation * history of psychiatric disorders * sleep disorders (e.g. insomnia, osas, ren or non-rem behavioural disorders) * medication affecting the physiological sleep pattern